Time to Prostate Specific Antigen Recurrence After Radical Prostatectomy and Risk of Prostate Cancer Specific Mortality
- 31 October 2006
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 176 (4), 1404-1408
- https://doi.org/10.1016/j.juro.2006.06.017
Abstract
In patients treated with radical prostatectomy who have biochemical recurrence we have previously reported that time from surgery to biochemical recurrence and postoperative prostate specific antigen doubling time are significantly related to the risk of prostate cancer death. We performed a more thorough examination of the association of time from surgery to biochemical recurrence and the risk of prostate cancer death. We retrospectively studied the records of 379 patients treated with radical prostatectomy between 1982 and 2000 who had had biochemical recurrence. We examined the association of time from surgery to prostate specific antigen recurrence and prostate specific antigen doubling time, and the risk of prostate cancer death using the Spearman correlation and Cox proportional hazards regression, respectively. Longer time from surgery to prostate specific antigen recurrence was associated with a slower prostate specific antigen doubling time (Spearman r = 0.36, p <0.001) and a decreased risk of prostate cancer death (RR 0.76, 95% CI 0.66 to 0.88, p <0.001). The 15-year actuarial prostate cancer specific survival rate after biochemical recurrence in patients with recurrence at 3 years or less was 41% (95% CI 29 to 53) compared to 87% (95% CI 75 to 93) in patients with recurrence more than 3 years after radical prostatectomy. On multivariate analysis a shorter time from surgery to prostate specific antigen recurrence was associated with an increased risk of prostate cancer death (3 or less vs more than 3 years, RR 2.70, 95% CI 1.37 to 5.31, p = 0.004). Earlier prostate specific antigen recurrence is associated with an increased risk of prostate cancer death. These data suggest that perhaps time to prostate specific antigen recurrence may be a reasonable intermediate end point in patients treated with radical prostatectomy, although this must be validated in other studies.Keywords
This publication has 14 references indexed in Scilit:
- Risk of Prostate Cancer–Specific Mortality Following Biochemical Recurrence After Radical ProstatectomyJAMA, 2005
- VALIDATION OF INCREASING PROSTATE SPECIFIC ANTIGEN AS A PREDICTOR OF PROSTATE CANCER DEATH AFTER TREATMENT OF LOCALIZED PROSTATE CANCER WITH SURGERY OR RADIATIONJournal of Urology, 2004
- PREDICTORS OF METASTATIC DISEASE IN MEN WITH BIOCHEMICAL FAILURE FOLLOWING RADICAL PROSTATECTOMYJournal of Urology, 2004
- Salvage Radiotherapy for Recurrent Prostate Cancer After Radical ProstatectomyJAMA, 2004
- The Long-Term Clinical Impact of Biochemical Recurrence of Prostate Cancer 5 or More Years After Radical ProstatectomyJournal of Urology, 2003
- Surrogate End Point for Prostate Cancer-Specific Mortality After Radical Prostatectomy or Radiation TherapyJNCI Journal of the National Cancer Institute, 2003
- Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomyUrology, 2003
- ACCURACY OF PREDICTING LONG-TERM PROSTATE SPECIFIC ANTIGEN OUTCOME BASED ON EARLY PROSTATE SPECIFIC ANTIGEN RECURRENCE RESULTS AFTER RADICAL PROSTATECTOMYJournal of Urology, 2001
- DEFINING PROSTATE SPECIFIC ANTIGEN PROGRESSION AFTER RADICAL PROSTATECTOMY: WHAT IS THE MOST APPROPRIATE CUT POINT?Journal of Urology, 2001
- Natural History of Progression After PSA Elevation Following Radical ProstatectomyJAMA, 1999